Rhodium-Catalyzed Homogeneous Asymmetric Hydrogenation of Naphthol Derivatives
Shuxin Zhang, Linhong Long, Zeyu Li, Yan‐Mei He, Shan Li, Hui Chen, Wei Hao, Qing‐Hua Fan
Abstract
Due to their strong aromaticity and difficulties in chemo-, regio-, and enantioselectivity control, asymmetric hydrogenation of naphthol derivatives to 1,2,3,4-tetrahydronaphthols has remained a long-standing challenge. Herein, we report the first example of homogeneous asymmetric hydrogenation of naphthol derivatives catalyzed by tethered rhodium-diamine catalysts, affording a wide array of optically pure 1,2,3,4-tetrahydronaphthols in high yields with excellent regio-, chemo-, and enantioselectivities (up to 98% yield and >99% ee). Mechanistic studies with experimental and computational approaches reveal that fluorinated solvent 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) plays vital roles in the control of reactivity and selectivity, and 1-naphthol is reduced via a cascade reaction pathway, including dearomative tautomerization, 1,4-hydride addition, and 1,2-hydride addition in sequence. A novel synergistic activation mode was proposed in which HFIP assists a synergistic activation of both the hydrogen molecule and naphthol in the presence of a base, and the in situ-generated fleeting keto tautomer is immediately trapped and reduced by the Rh(III)-H species before it escapes from the solvent cage. This protocol provides a straightforward and practical pathway for the synthesis of key intermediates for several chiral drugs. Particularly, optically pure Nadolol, a drug for the treatment of hypertension, angina pectoris, congestive heart failure, and certain arrhythmias, is enantioselectively synthesized for the first time.